Figure 6

BFA and EHT-1864 reduce VEGF secretion, slow tumor growth, and increase the survival of mice harboring S100β-v-erbB/p53^−/− allografts. (a) Plasma VEGF levels of mice growing glioma tumor allografts treated either with vehicle (n=3), BFA (n=4), or EHT-1864 (n=4) (7 days). Data points are presented as the mean±s.d. (*P<0.001) (b) Gross appearance of tumors extracted 12 to 20 days after treatment initiation with vehicle (n=5), BFA (n=4), or EHT-1864 (n=4). (c) Estimated tumor volumes of S100β-v-erbB/p53^−/− allografts treated with vehicle (n=8) or BFA (n=7). Dashed line indicates end of treatment. When comparing all vehicles against all BFA treated allografts, P<0.009. (d) Tumor volume of TSC1 allografts treated with vehicle (n=8) or EHT-1864 (n=7). Dashed line indicates end of treatment. When comparing all vehicles against all EHT-1864 treated allografts, P<0.0004. (e) Kaplan–Meier survival curve of mice that grew glioma tumor allografts and were treated either with vehicle (n=8), BFA (n=7), or EHT-1864 (n=7). Log-rank tests comparing the survival curves for vehicle control against those of BFA and EHT-184 yield P-values of 0.0056 and 0.0017, respectively.